| 臺大學術典藏 |
2021-03-11T08:34:15Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-09T08:07:35Z |
Pulmonary granulomas: Give it a whorl
|
WEI-YUNG LO; SHENG-KAI LIANG; LI-TA KENG; Hsien-Neng Huang , Huan-Jang Ko |
| 臺大學術典藏 |
2021-02-08T08:05:08Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
Jen-Chung Ko;Sheng-Kai Liang;Li-Ta Keng;Chia-Hao Chang;Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu; JEN-CHUNG KO; SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Yueh-Feng Wen ; Meng-Rui Lee ; Ching-Yao Yang ; Jann-Yuan Wang ; Jin-Yuan Shih ; Chong-Jen Yu |
| 臺大學術典藏 |
2021-02-02T09:21:39Z |
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
|
SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen, Yueh Feng; MENG-RUI LEE; Yang, Ching Yao; JANN-YUAN WANG; JEN-CHUNG KO; JIN-YUAN SHIH; CHONG-JEN YU |
| 臺大學術典藏 |
2021-01-19T12:08:48Z |
Pulmonary granulomas: Give it a whorl
|
LI-TA KENG; WEI-YUNG LO; Hsien-Neng Huang; Ko, Huan Jang; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:22Z |
Otitis media and otomastoiditis caused by Mycobacterium massiliense (Mycobacterium abscessus subsp. bolletii)
|
Hsueh P.-R.; Lee L.-N.; SHENG-KAI LIANG; Liao C.-H.; Huang Y.-T.; Lee M.-R.; Tsai H.-Y.; Cheng A.; Liu C.-Y. |
| 臺大學術典藏 |
2021-01-08T03:40:21Z |
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells
|
Pan C.-H.; Chang Y.-F.; Lee M.-S.; Wen B.-C.; Ko J.-C.; SHENG-KAI LIANG; Liang M.-C. |
| 臺大學術典藏 |
2021-01-08T03:40:21Z |
Bacteraemia caused by Mycobacterium abscessus subsp. abscessus and M. abscessus subsp. bolletii: Clinical features and susceptibilities of the isolates
|
Lee M.-R.; Ko J.-C.; SHENG-KAI LIANG; Lee S.-W.; Yen D.H.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-01-08T03:40:21Z |
Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy
|
SHENG-KAI LIANG; Chen J.Y.P.; Shu C.-C.; Keng L.-T.; Lin C.-K.; Chang L.-Y.; Chang C.-H.; Wang J.-Y.; Yu C.-J.; Lee L.-N. |
| 臺大學術典藏 |
2021-01-08T03:40:21Z |
Clinical characteristics of bacteraemia caused by Lactobacillus spp. and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2000-2014
|
Lee M.-R.; Tsai C.-J.; SHENG-KAI LIANG; Lin C.-K.; Huang Y.-T.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Foxm1 Transcription Factor Regulates Lung Adenocarcinoma Development
|
SHENG-KAI LIANG; Chao S.-Y.; Li C.-C.; Ip K.-U.; Lin Y.-K.; Hsu C.-C.; Hsu P.-C.; Wang I.-C. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study
|
Shih J.-Y.; Ko J.-C.; Ho C.-C.; Liao W.-Y.; Lee M.-R.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Wang H.-C.; Hsu C.-L.; Jerng J.-S.; Chen Y.-F.; Chang H.-T.; Chen I.-C.; Cheng J.-C.; SHENG-KAI LIANG; Lin S.-Y.; Keng L.-T.; Chung K.-P.; Kuo P.-H.; Wu H.-D.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Shih J.-Y.; Ko J.-C.; Lee M.-R.; Keng L.-T.; Hsieh M.-S.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:19Z |
Pulmonary granulomas: Give it a whorl
|
Keng L.-T.; Lo W.-Y.; Huang H.-N.; Ko H.-J.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:19Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
SHENG-KAI LIANG; Ko J.-C.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T03:40:19Z |
Albers-Sch?nberg disease
|
Keng L.-T.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T03:40:18Z |
Predicting lung cancer occurrence in never-smoking females in Asia: TNSF-SQ, a prediction model
|
Chien L.-H.; Chen C.-H.; Chen T.-Y.; Chang G.-C.; Tsai Y.-H.; Hsiao C.-F.; Chen K.-Y.; Su W.-C.; Wang W.-C.; Huang M.-S.; Chen Y.-M.; Chen C.-Y.; SHENG-KAI LIANG; Chen C.-Y.; Wang C.-L.; Lee M.-H.; Chung R.-H.; Tsai F.-Y.; Hu J.-W.; Katki H.A.; Chatterjee N.; Chanock S.J.; Rothman N.; Lan Q.; Yang P.-C.; Chen C.-J.; Chang I.-S.; Hsiung C.A. |
| 臺大學術典藏 |
2021-01-08T02:56:47Z |
Bronchial atresia
|
Li-Ta Keng;Liang S.-K.; LI-TA KENG; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-01-08T02:56:46Z |
Significant clinical factors associated with long-term mortality in critical cancer patients requiring prolonged mechanical ventilation
|
Yen-Fu Chen; I-Chun Chen; Jui-Chen Cheng; SHENG-KAI LIANG; Shu-Yung Lin; Li-Ta Keng;Chung K.-P.;Lin S.-Y.;Liang S.-K.;Cheng J.-C.;Chen I.-C.;Chen Y.-F.;Chang H.-T.;Hsu C.-L.;Jerng J.-S.;Wang H.-C.;Kuo P.-H.;Wu H.-D.;Shih J.-Y.;Yu C.-J.; LI-TA KENG; Kuei-Pin Chung; Hou-Tai Chang; Chia-Lin Hsu; Jih-Shuin Jerng; Hao-Chien Wang; Ping-Hung Kuo; Huey-Dong Wu; Jin-Yuan Shih; Chong-Jen Yu |
| 臺大學術典藏 |
2021-01-08T02:56:45Z |
Albers-Schönberg disease
|
SHENG-KAI LIANG; LI-TA KENG; Li-Ta Keng;Liang S.-K. |
| 臺大學術典藏 |
2019-12-23T03:27:21Z |
Albers-Schonberg disease
|
SHENG KAI LIANG;LI-TA KENG; LI-TA KENG; SHENG KAI LIANG |
| 臺大學術典藏 |
2019-12-23T03:27:21Z |
Albers-Schonberg disease
|
SHENG KAI LIANG;LI-TA KENG; LI-TA KENG; SHENG KAI LIANG |
| 臺大學術典藏 |
2019-12-18T06:15:22Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Yang, James Chih-Hsin; Shih, Jin-Yuan;SHENG KAI LIANG;JEN-CHUNG KO; JEN-CHUNG KO; SHENG KAI LIANG; Yang, James Chih-Hsin; Shih, Jin-Yuan |
| 臺大學術典藏 |
2019-12-18T06:15:22Z |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Yang, James Chih-Hsin; Shih, Jin-Yuan;SHENG KAI LIANG;JEN-CHUNG KO; JEN-CHUNG KO; SHENG KAI LIANG; Yang, James Chih-Hsin; Shih, Jin-Yuan |
